AR038094A1 - Derivados de benzotiazol-4,7-dionas y benzooxazol-4,7-dionas, su uso para preparar un medicamento y composicion farmaceutica - Google Patents
Derivados de benzotiazol-4,7-dionas y benzooxazol-4,7-dionas, su uso para preparar un medicamento y composicion farmaceuticaInfo
- Publication number
- AR038094A1 AR038094A1 ARP020105135A ARP020105135A AR038094A1 AR 038094 A1 AR038094 A1 AR 038094A1 AR P020105135 A ARP020105135 A AR P020105135A AR P020105135 A ARP020105135 A AR P020105135A AR 038094 A1 AR038094 A1 AR 038094A1
- Authority
- AR
- Argentina
- Prior art keywords
- radical
- alkyl
- atom
- independently selected
- heterocycle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Uso de los compuestos de fórmula general (1) según cláusula 1 y composición farmacéutica que los contiene. De acuerdo con la presente, los compuestos de fórmula general (1) se pueden usar en particular para preparar un medicamento destinado al tratamiento del cáncer. Los compuestos de fórmula (1) son inhibidores de cdc25 fosfatasa. Reivindicación 1: Uso de un compuesto caracterizado porque dicho compuesto tiene la fórmula general (1) en donde: R1 representa un átomo de H o un radical alquilo, alcoxialquilo, alquiltiolaquilo, cicloalquilo, -(CH2)-X-Y, -(CH2)-Z-NR5R6 o un radical -CHR35R36 en donde R35 y R36 forman junto con el átomo de carbono al cual están unidos un radical indanilo o tetralinilo, o también R35 y R36 forman junto con el átomo de carbono al cual están unidos un heterociclo saturado que contiene 5 a 7 miembros y 1 o 2 heteroátomos seleccionados entre O, N, y S, estando los átomos de N de dicho heterociclo opcionalmente sustituidos por radicales seleccionados entre los radicales alquilo y el radical bencilo, R1, cuando W representa O, puede representar además un radical arilo carbocíclico opcionalmente sustituido entre 1 y 3 veces por sustituyentes seleccionados independientemente entre un átomo de halógeno y un radical alquilo, haloalquilo o alcoxi, X representa un enlace o un radical alquileno lineal o ramificado que contiene 1 a 5 átomos de carbono, Y representa un sistema cíclico saturado que contiene carbono con entre 1 y 3 anillos condensados seleccionados independientemente entre anillos con 3 a 7 miembros, o Y representa un heterociclo saturado que contiene 1 o 2 heteroátomos seleccionados independientemente entre O, N y S y unido al radical X por un miembro N o CH, conteniendo dicho heterociclo saturado además 2 a 6 miembros adicionales seleccionados independientemente entre -CHR7-, -CO-, -NR8-, -O- y -S-, donde R7 representa un átomo de H o un radical alquilo y R8 representa un átomo de H o un radical alquilo o aralquilo, o también Y representa un radical arilo carbocíclico o heterocíclico opcionalmente sustituido entre 1 y 3 veces por sustituyentes seleccionados independientemente entre el grupo formado por un átomo de halógeno, un radical alquilo, un radical haloalquilo, un radical alcoxi, un radical haloalcoxi, un radical hidroxi, un radical nitro, un radical ciano, el radical fenilo, un radical SO2NHR9 y un radical NR10R11, donde R9 representa un átomo de H o un radical alquilo o fenilo, y R10 y R11 representan independientemente radicales alquilo, Z representa un enlace o un radical alquileno lineal o ramificado que contiene C1-5, R5 y R6 se seleccionan independientemente entre un átomo de H, un radical alquilo, aralquilo o -(CH2)n-OH en donde n representa un número entero del 1 al 6, o R5 representa un radical alcoxicarbonilo, haloalcoxicarbonilo o aralcoxicarbonilo y R6 representa un átomo de H o a metilo, o además R5 y R6 forman junto con el átomo de N un heterociclo con entre 4 y 7 miembros que comprenden 1 o 2 heteroátomos, donde los miembros necesarios para completar el heterociclo se seleccionan independientemente entre los radicales -CR12R13-, -O-, -S-, y -NR14, donde R12 y R13 representan independientemente cada vez que ocurren un átomo de H o un radical alquilo, y R14 representa un átomo de H o un radical alquilo o aralquilo, o también R14 representa un radical fenilo opcionalmente sustituido entre 1 y 3 veces por sustituyentes seleccionados independientemente entre un átomo de halógeno y un radical alquilo o alcoxi, R2 representa un átomo de H o un radical alquilo o aralquilo; o además R1 y R2 forman junto con el átomo de N un heterociclo con 4 a 8 miembros que comprende 1 o 2 heteroátomos, donde los miembros necesarios para completar el heterociclo se seleccionan independientemente entre los radicales -CR15R16-, -O-, -S-, y -NR17-, donde R15 y R16 representan independientemente cada vez que ocurren un átomo de H o un radical alquilo, y R17 representa un átomo de H o un radical alquilo o aralquilo; R3 representa un átomo de H, átomo de halógeno, o un radical alquilo, haloalquilo, alcoxi o alquiltio; R4 representa un radical alquilo, cicloalquilo, cicloalquilalquilo, ciano, amino, -CH2-COOR18, -CH2-CO-NR19R20 o -CH2-NR21R22, o también R4 representa un radical arilo carbocíclico o heterocíclico opcionalmente sustituido entre 1 y 4 veces por sustituyentes seleccionados independientemente entre un átomo de halógeno y un radical alquilo, haloalquilo, alcoxi o NR37R38, o R4 también representa un fenilo con dos sustituyentes que forman juntos metilendioxi o etilendioxi; R18 representa un átomo de H o un radical alquilo, R19 representa un átomo de H, un radical alquilo o un radical aralquilo cuyo grupo arilo es opcionalmente sustituido entre 1 y 3 veces por sustituyentes seleccionados independientemente entre el grupo formado por un átomo de halógeno, un radical alquilo, un radical haloalquilo, un radical alcoxi, un radical haloalcoxi, un radical hidroxi, un radical nitro, un radical ciano, el radical fenilo, un radical SO2NHR23 y un radical NR24R25, donde R23 representa un átomo de H o un radical alquilo o fenilo, y R24 y R25 representan independientemente radicales alquilo, R20 representa un átomo de H o un radical alquilo, o además R19 y R20 forman junto con el átomo de N un heterociclo con entre 4 y 7 miembros que comprenden 1 o 2 heteroátomos, donde los miembros necesarios para completar el heterociclo se seleccionan independientemente entre los radicales -CR26R27-, -O-, -S-, -NR28-, donde R26 y R27 representan independientemente cada vez que ocurren un átomo de H o un radical alquilo, y R28 representa un átomo de H o un radical alquilo o aralquilo, o también R28 representa un radical fenilo opcionalmente sustituido entren 1 y 3 veces por sustituyentes seleccionados independientemente entre un átomo de halógeno y un radical alquilo o alcoxi, R21 representa un átomo de H, un radical alquilo o un radical aralquilo cuyo grupo arilo es opcionalmente sustituido entre 1 y 3 veces por sustituyentes seleccionados independientemente entre el grupo formado por un átomo de halógeno, un radical alquilo, un radical haloalquilo, un radical alcoxi, un radical haloalcoxi, un radical hidroxi, un radical nitro, un radical ciano, el radical fenilo, un radical SO2NHR29 y un radical NR30R31, donde R29 representa un átomo de H o un radical alquilo o fenilo, y R30 y R31 representan independientemente radicales alquilo, R22 representa un átomo de H o un radical alquilo, o además R21 y R22 forman junto con el átomo de N un heterociclo con entre 4 y 7 miembros que comprenden 1 o 2 heteroátomos, donde los miembros necesarios para completar el heterociclo se seleccionan independientemente entre los radicales -CR32R33, -O-, -S- y -NR34, donde R32.y R33 representan independientemente cada vez que ocurren un átomo de H o un radical alquilo, y R34 representa un átomo de H, un radical alquilo o aralquilo, o también R34 representa un radical fenilo opcionalmente sustituido entre 1 y 3 veces por sustituyentes seleccionados independientemente entre un átomo de halógeno y un radical alquilo o alcoxi, R37 y R38 se seleccionan independientemente entre un átomo de H y un radical alquilo o R37 y R38 forman junto con el átomo de N un heterociclo con entre 4 y 7 miembros que comprenden 1 o 2 heteroátomos, donde los miembros necesarios para completar el heterociclo se seleccionan independientemente entre los radicales -CR39R40-, -O-, -S- y -NR41-, donde R39 y R40 representan independientemente cada vez que ocurren un átomo de H o un radical alquilo, y R41 representa un átomo de H o un radical alquilo y W representa O o S; o una sal aceptable para uso farmacéutico de un compuesto de fórmula general (1) para preparar un medicamento destinado a inhibir cdc25 fosfatasas y/o CD45 fosfatasa. Reivindicación 2: Uso de un compuesto de fórmula general (1) de acuerdo con la reivindicación 1, o de una sal aceptable para uso farmacéutico de dicho compuesto caracterizado porque es para preparar un medicamento destinado a tratar una enfermedad seleccionada entre las siguientes enfermedades/trastornos: enfermedades tumorales proliferativas, y en particular cáncer, enfermedades proliferativas no tumorales, enfermedades neurodegenerativas, enfermedades parasitarias, infecciones virales, alopecia espontánea, alopecia inducida por productos exógenos, alopecia inducida por radiación, enfermedades autoinmunes, rechazo de transplantes, enfermedades inflamatorias y alergias.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0116889A FR2834289B1 (fr) | 2001-12-27 | 2001-12-27 | Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques |
FR0209415 | 2002-07-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR038094A1 true AR038094A1 (es) | 2004-12-29 |
Family
ID=26213311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020105135A AR038094A1 (es) | 2001-12-27 | 2002-12-27 | Derivados de benzotiazol-4,7-dionas y benzooxazol-4,7-dionas, su uso para preparar un medicamento y composicion farmaceutica |
Country Status (24)
Country | Link |
---|---|
US (3) | US20070255063A1 (es) |
EP (1) | EP1461326B1 (es) |
JP (1) | JP4491238B2 (es) |
KR (1) | KR101011300B1 (es) |
CN (1) | CN100425600C (es) |
AR (1) | AR038094A1 (es) |
AT (1) | ATE368654T1 (es) |
AU (1) | AU2002364485B2 (es) |
BR (1) | BR0215336A (es) |
CA (1) | CA2471713A1 (es) |
CZ (1) | CZ2004825A3 (es) |
DE (1) | DE60221570T2 (es) |
DK (1) | DK1461326T3 (es) |
ES (1) | ES2290359T3 (es) |
HU (1) | HUP0600238A3 (es) |
IL (1) | IL162385A (es) |
IS (1) | IS2490B (es) |
MX (1) | MXPA04006239A (es) |
NO (1) | NO326888B1 (es) |
NZ (1) | NZ533454A (es) |
PL (1) | PL371365A1 (es) |
PT (1) | PT1461326E (es) |
RU (1) | RU2326664C2 (es) |
WO (1) | WO2003055868A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2834289B1 (fr) | 2001-12-27 | 2004-03-19 | Sod Conseils Rech Applic | Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques |
FR2856686A1 (fr) * | 2003-06-25 | 2004-12-31 | Sod Conseils Rech Applic | Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation |
FR2856688B1 (fr) * | 2003-06-25 | 2008-05-30 | Sod Conseils Rech Applic | PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX |
GB0329608D0 (en) * | 2003-12-22 | 2004-01-28 | Univ Nottingham | A novel method for embryo and animal production |
FR2877667B1 (fr) | 2004-11-05 | 2007-03-23 | Sod Conseils Rech Applic | Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques |
FR2879598B1 (fr) | 2004-12-17 | 2007-03-30 | Sod Conseils Rech Applic | Inhibiteurs de phosphatases cdc25 |
FR2918665B1 (fr) * | 2007-07-13 | 2009-10-02 | Sod Conseils Rech Applic | Derives de tri-amino-pyrimidine cyclobutenedione comme inhibiteurs de phosphatase cdc25 |
FR2945532A1 (fr) * | 2009-05-15 | 2010-11-19 | Ipsen Pharma Sas | Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25 |
CN106928212B (zh) * | 2017-02-28 | 2020-03-17 | 牡丹江医学院 | 一种用于治疗阑尾炎的药物及其制备方法和应用 |
CN109485646A (zh) * | 2018-12-12 | 2019-03-19 | 中国药科大学 | 一种苯并噻唑醌类化合物及其制备方法和用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1534275A (en) * | 1976-01-30 | 1978-11-29 | Shell Int Research | Herbicidal compositions containing 1,4-quinones or derivatives thereof |
US5523430A (en) * | 1994-04-14 | 1996-06-04 | Bristol-Myers Squibb Company | Protein farnesyl transferase inhibitors |
AU2003999A (en) * | 1997-12-19 | 1999-07-12 | Advanced Research And Technology Institute, Inc. | Modulators of ryanodine receptors comprising 2-(aryl)-4,7-dioxobenzothiazoles and analogues thereof |
ATE305785T1 (de) * | 1999-12-21 | 2005-10-15 | Cd45 hemmer | |
FR2825278A1 (fr) * | 2001-05-30 | 2002-12-06 | Sod Conseils Rech Applic | Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer |
FR2834289B1 (fr) * | 2001-12-27 | 2004-03-19 | Sod Conseils Rech Applic | Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques |
FR2856686A1 (fr) * | 2003-06-25 | 2004-12-31 | Sod Conseils Rech Applic | Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation |
FR2856688B1 (fr) * | 2003-06-25 | 2008-05-30 | Sod Conseils Rech Applic | PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX |
DE202004004401U1 (de) * | 2004-03-20 | 2004-05-19 | Groz-Beckert Kg | Geprägte Tuftingnadel |
-
2002
- 2002-12-24 AT AT02799849T patent/ATE368654T1/de active
- 2002-12-24 NZ NZ533454A patent/NZ533454A/en not_active IP Right Cessation
- 2002-12-24 DE DE60221570T patent/DE60221570T2/de not_active Expired - Lifetime
- 2002-12-24 CA CA002471713A patent/CA2471713A1/fr not_active Abandoned
- 2002-12-24 KR KR1020047010146A patent/KR101011300B1/ko not_active IP Right Cessation
- 2002-12-24 PT PT02799849T patent/PT1461326E/pt unknown
- 2002-12-24 AU AU2002364485A patent/AU2002364485B2/en not_active Ceased
- 2002-12-24 CN CNB028263669A patent/CN100425600C/zh not_active Expired - Fee Related
- 2002-12-24 PL PL02371365A patent/PL371365A1/xx not_active Application Discontinuation
- 2002-12-24 BR BR0215336-0A patent/BR0215336A/pt active Search and Examination
- 2002-12-24 JP JP2003556399A patent/JP4491238B2/ja not_active Expired - Fee Related
- 2002-12-24 WO PCT/FR2002/004544 patent/WO2003055868A1/fr active IP Right Grant
- 2002-12-24 DK DK02799849T patent/DK1461326T3/da active
- 2002-12-24 MX MXPA04006239A patent/MXPA04006239A/es active IP Right Grant
- 2002-12-24 RU RU2004122911/15A patent/RU2326664C2/ru not_active IP Right Cessation
- 2002-12-24 HU HU0600238A patent/HUP0600238A3/hu unknown
- 2002-12-24 CZ CZ2004825A patent/CZ2004825A3/cs unknown
- 2002-12-24 EP EP02799849A patent/EP1461326B1/fr not_active Expired - Lifetime
- 2002-12-24 ES ES02799849T patent/ES2290359T3/es not_active Expired - Lifetime
- 2002-12-27 AR ARP020105135A patent/AR038094A1/es unknown
-
2004
- 2004-06-07 IL IL162385A patent/IL162385A/en not_active IP Right Cessation
- 2004-06-23 IS IS7334A patent/IS2490B/is unknown
- 2004-07-26 NO NO20043173A patent/NO326888B1/no not_active IP Right Cessation
-
2007
- 2007-05-22 US US11/752,180 patent/US20070255063A1/en not_active Abandoned
-
2008
- 2008-10-03 US US12/245,549 patent/US20090082345A1/en not_active Abandoned
- 2008-10-06 US US12/246,294 patent/US20090131428A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
AR039659A1 (es) | Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa | |
AR094537A1 (es) | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa | |
AR065499A1 (es) | Inhibidores de serino proteasas.composiciones farmaceuticas | |
AR049092A1 (es) | Derivados de tetrahidronaftiridina como ligandos del receptor h3 de histamina | |
AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
AR057131A1 (es) | Derivados de purina como inmunomodulador | |
AR035069A1 (es) | Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento | |
AR086367A1 (es) | Compuestos de pirrolidinil urea y pirrolidinil tiourea como inhibidores de cinasa trka | |
AR016429A1 (es) | Compuesto derivado de acido hidroxamico como inhibidores de metaloproteasa de matriz (mmp), composiciones farmaceuticas y formulaciones veterinarias, usopara la preparacion de composiciones y formulaciones, compuesto intermediario, procedimiento de preparacion del compuesto. | |
BR0010476A (pt) | Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais | |
AR055053A1 (es) | Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas. | |
ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
AR046792A1 (es) | Fenilalanina-amidas sustituidas por heteroaroilo, un procedimiento para su preparacion, utilizacion de las mismas como herbicidas y productos fitosa-nitarios que los contienen como principio activo | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
EA200701780A1 (ru) | Противоопухолевое средство | |
AR038094A1 (es) | Derivados de benzotiazol-4,7-dionas y benzooxazol-4,7-dionas, su uso para preparar un medicamento y composicion farmaceutica | |
DK1664016T3 (da) | Terapeutiske midler, der er anvendelige til behandling af smerter | |
AR054045A1 (es) | Compuestos benzoimidazol sustituidos con actividad dual no inhibitoria y mu opioide agonista | |
AR082968A1 (es) | Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto | |
ECSP099767A (es) | Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |